NCT05572177 Feasibility of a Smartphone Application for Asthma Self-management
| NCT ID | NCT05572177 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of South Florida |
| Condition | Asthma Chronic |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2023-06-26 |
| Primary Completion | 2025-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2023-06-26 with a primary completion date of 2025-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary goal of this project is to determine the feasibility, acceptability, and adherence of a smartphone application for improving asthma self-management in a pilot randomized controlled trial (RCT). The app is specifically designed to appeal to adolescents. Adolescents with persistent asthma will be randomized to receive: 1) standard-of-care or 2) the self-management app in addition to standard-of-care. Feasibility will be assessed by the ability to recruit and retain subjects, technical barriers to implementation, and the appropriateness of the intervention among adolescents and providers. The acceptability of the intervention will be determined by appraising perceived usefulness, entertainment, and ease of use of the app. Adherence to usage of the app over a 6-month period will be assessed by examining the frequency of app usage and the features that were used, and the extent of data regarding self-management that was entered. A secondary objective is to obtain preliminary estimates of effectiveness of the app on clinical outcomes (ACT score, spirometry, CHSA-C, exacerbations, and medication adherence) relative to standard-of-care. It is hypothesized that the app will result in a high level of adherence and will be a feasible and acceptable intervention to improve self-management among adolescents with persistent asthma.
Eligibility Criteria
Inclusion Criteria: * At least 12 and less than 18 years at enrollment * Established mild, moderate, or severe persistent asthma with a diagnosis verified by clinic physicians * Speak English * Not planning on moving out of the Tampa Bay area during the trial period * Must have a suitable iPhone or Android device available to use with the app Exclusion Criteria: * Having mental or other development disorder that may make self-management of a chronic condition difficult * Having other chronic lung disease or one or more of the following disorders including cystic fibrosis, neuromuscular disease, immunodeficiency or autoimmune disorders, blindness or severe vision impairment that may interfere with the ability to use the mobile app * Having participated in the app development phase of the funded project
Contact & Investigator
Amy Alman, PhD
PRINCIPAL INVESTIGATOR
University of South Florida
Frequently Asked Questions
Who can join the NCT05572177 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, up to 17 Years, studying Asthma Chronic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05572177 currently recruiting?
Yes, NCT05572177 is actively recruiting participants. Contact the research team at diptik@usf.edu for enrollment information.
Where is the NCT05572177 trial being conducted?
This trial is being conducted at Tampa, United States.
Who is sponsoring the NCT05572177 clinical trial?
NCT05572177 is sponsored by University of South Florida. The principal investigator is Amy Alman, PhD at University of South Florida. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.